Erbitux
Drug
Merck KGaA
Total Payments
$24,709
Transactions
84
Doctors
26
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3,968 | 1 | 1 |
| 2022 | $8,400 | 3 | 2 |
| 2019 | $9,581 | 4 | 2 |
| 2017 | $2,761 | 76 | 23 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,488 | 3 | 54.6% |
| Consulting Fee | $8,400 | 3 | 34.0% |
| Food and Beverage | $2,794 | 77 | 11.3% |
| Travel and Lodging | $27.46 | 1 | 0.1% |
Ad
Manufacturing Companies
- Merck KGaA $21,948
- EMD Serono Research & Development Institute $2,761
Product Information
- Type Drug
- Total Payments $24,709
- Total Doctors 26
- Transactions 84
About Erbitux
Erbitux is a drug associated with $24,709 in payments to 26 healthcare providers, recorded across 84 transactions in the CMS Open Payments database. The primary manufacturer is Merck KGaA.
Payment data is available from 2017 to 2024. In 2024, $3,968 was paid across 1 transactions to 1 doctors.
The most common payment nature for Erbitux is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($13,488, 54.6% of total).